Survodutide
USAN adopted: February 28, 2024
Developer: Boehringer Ingelheim (BI 456906; licensed from Zealand Pharma)
Class: Dual GLP-1 receptor agonist + glucagon receptor (GCGR) agonist
Route: Once-weekly subcutaneous injection
Phase: Phase 3 (filing expected early 2026; not yet approved)
Name note: The queue slug “survutide” is an artifact. The correct USAN name is survodutide (BI 456906). Boehringer Ingelheim is the sole sponsor; Zealand Pharma licensed the molecule. Same compound — not two different drugs.
TL;DR
Survodutide is a dual GLP-1/GCGR agonist with strongest Phase 2 evidence in obesity (~15% weight loss at 46 weeks) and MASH (62% resolution at 48 weeks). Its glucagon component theoretically adds energy expenditure beyond what GLP-1 monotherapy achieves, but also raises an unresolved concern about lean mass catabolism. Phase 3 results are pending; no body composition DXA data exist. GI adverse events are the primary tolerability barrier (25% discontinuation).
Why it matters for Vitals
Survodutide sits at the intersection of three core Vitals domains:
- Body composition — The GCGR catabolic pathway is theoretically concerning for lean mass. No DXA data published. For any Vitals user prioritizing muscle preservation, this is an unresolved risk flag.
- Metabolic optimization — GLP-1 + GCGR dual mechanism offers a distinct pathway from tirzepatide (GLP-1/GIP) or retatrutide (GLP-1/GIP/glucagon triple). Relevant for coaching logic when users are choosing among GLP-1 class agents.
- Liver health — MASH Phase 2 biopsy data are strong (62% resolution). If Phase 3 confirms this, survodutide becomes the preferred GLP-1 option for users with metabolic-associated fatty liver disease.
Coaching flags:
- No body composition data → assume uncertain lean mass impact; emphasize resistance training and protein intake
- GI AEs peak during titration (weeks 1–8) → wearable HRV/suppression patterns will likely correlate
- Heart rate elevation (~3 bpm class effect) → monitor for sustained elevation above personal baseline
Key facts
| Parameter | Value |
|---|---|
| Half-life | ~6 days (144 h); once-weekly SC |
| Albumin binding | >99% (C18 fatty di-acid acylation) |
| Active metabolites | None identified |
| Dose proportionality | Linear (0.3–6.0 mg range) |
| Hepatic impairment | No dose adjustment needed (Child-Pugh A–C) |
| Oral bioavailability | Zero (peptide; GI degradation) |
| Phase 3 target doses | 3.6 mg and 6.0 mg qw |
| Regulatory status | FDA BTD (Oct 2024, MASH); filing early 2026 |
Mechanism summary
Survodutide activates GLP-1R (~8× more potently than GCGR) and GCGR simultaneously as a single unimolecular peptide.
GLP-1R agonism produces:
- Glucose-dependent insulin secretion
- Alpha-cell glucagon suppression
- Delayed gastric emptying
- Hypothalamic appetite suppression
- Reduced food intake
GCGR agonism produces:
- Hepatic fatty acid oxidation via cAMP/PKA signaling
- Reduced de novo lipogenesis and VLDL/triglyceride secretion
- Circulating amino acid reduction (increased ureagenesis)
- Circulating FGF-21 elevation
- Increased energy expenditure (hypothesized to be hepatic substrate cycling, not classical BAT thermogenesis)
The dual mechanism is designed to exceed GLP-1 monotherapy on weight loss through two complementary pathways: reduced intake (GLP-1R) + increased expenditure (GCGR).
For the dual GLP-1/GCGR mechanism framework, see GLP-1 GIP Glucagon.
What the current evidence suggests
Obesity Phase 2 (no T2D) — HIGH confidence
RCT, n=387, 46 weeks, BMI ≥27 without T2D (Lancet D&E 2024, PMID 38330987):
| Dose (qw SC) | Bodyweight change | Placebo-subtracted |
|---|---|---|
| 4.8 mg | −14.9% | −12.1% |
| Placebo | −2.8% | — |
83% of participants on 4.8 mg achieved ≥5% weight loss. Overall dropout ~40%; treatment discontinuation due to AEs: 25% vs 4% placebo.
Obesity + T2D Phase 2 — HIGH confidence
RCT, n=411, 16 weeks, BMI 25–50 with T2D on metformin (Diabetologia 2023, PMID 38095657):
| Dose | Weight | HbA1c |
|---|---|---|
| 1.8 mg biw | −8.7% | −1.71% |
| Semaglutide 1 mg qw (comparator) | −5.3% | −1.47% |
Statistically greater weight loss than semaglutide at 16 weeks.
MASH Phase 2 (biopsy-confirmed) — HIGH confidence
RCT, n=293, 48 weeks, F1–F3 fibrosis (NEJM 2024, PMID 38847460):
| Dose | MASH resolution (no fibrosis worsening) | Fibrosis ≥1 stage improvement |
|---|---|---|
| 4.8 mg | 62% | 36% |
| Placebo | 14% | 22% |
Liver fat ≥30% reduction: 57–67% (survodutide) vs 14% (placebo).
Phase 3 status
SYNCHRONIZE-1 (obesity, n=726) and SYNCHRONIZE-2 (obesity + T2D, n=752) have baseline data published; efficacy results pending. Expected H1 2026. SYNCHRONIZE-CVOT is event-driven (cardiovascular outcomes).
Likely wearable / Vitals relevance
Evidence-backed
- Heart rate: GLP-1 class effect ~3 bpm elevation. Sustained HR >100 bpm resting or >20 bpm above personal baseline warrants flag.
- Weight trajectory: Connected scale data can track dose-dependent weight loss. Rapid >5% weekly loss is a dehydration risk flag.
- GI symptom logging: Self-reported nausea/vomiting/diarrhea peak during weeks 1–8 titration; indirect wearable signals via meal-timing irregularities and sleep continuity disruption.
- Sleep disruption: Titration-phase GI AEs suppress HRV and increase wake events.
Extrapolated (by class extension)
- HRV as autonomic stress proxy during caloric deficit and GI adversity periods
- CGM Glucose Management Indicator (GMI) trend for T2D population (survodutide-specific CGM data not published; applicable by class extension)
- Post-prandial HR pattern as proxy for gastric emptying effects
Not yet actionable
- Liver fat proxy from wearable metabolic inflexibility scores (no validated model)
- MASH/fibrosis detection from wearable biomarkers (not supported)
Risks and uncertainty
GI adverse events (well-established)
- Nausea: 66% (vs 23% placebo)
- Diarrhea: 49% (vs 23% placebo)
- Vomiting: 36% (vs 6% placebo)
- AE-related discontinuation: 25% (vs 4% placebo)
GCGR-specific concern (theoretical, unresolved)
The glucagon receptor stimulates gluconeogenesis and amino acid catabolism. No DXA or body composition data published. This is the primary uncertainty for Vitals users with muscle preservation goals. See GLP-1 Muscle Preservation and GLP-1 RA Skeletal Safety.
Class-level risks
- Heart rate elevation (~3 bpm mean)
- Thyroid C-cell tumor (FDA boxed warning; human relevance unproven)
- Gallbladder disease
- Pancreatitis (long-term GLP-1 data largely dispelling association)
- Hypoglycemia risk with insulin/secretagogues
- Aspiration risk during anesthesia (delayed gastric emptying)
Critical evidence gaps
| Gap | Implication for Vitals |
|---|---|
| No Phase 3 efficacy data | Coaching must not overstate weight loss potential |
| No body composition / DXA data | Lean mass uncertainty is an active coaching flag |
| No head-to-head vs tirzepatide or retatrutide | Comparative selection guidance is speculative |
| No CV outcome data | Cardiovascular safety not yet established |
| No long-term (>46-week) obesity data | Sustainability of effects unknown |
Best stack context
Survodutide occupies a specific niche in the GLP-1 landscape:
- vs Retatrutide: Retatrutide adds GIP + glucagon to GLP-1; survodutide adds glucagon only. No comparative data. Retatrutide currently leads on absolute efficacy (~28.7% Phase 3 weight loss).
- vs Tirzepatide (GLP-1/GIP): Distinct mechanisms — tirzepatide uses anorexic GIP signaling; survodutide uses thermogenic GCGR signaling. No head-to-head.
- vs Semaglutide (GLP-1 mono): Survodutide’s GCGR component theoretically provides greater energy expenditure. No head-to-head data.
- MASH priority: Survodutide has the strongest Phase 2 biopsy data among GLP-1 class agents and FDA BTD for non-cirrhotic MASH with fibrosis.
For a structured comparison of these agents, see
retatrutide-vs-semaglutide-vs-tirzepatide.md.
Universal recommendation across GLP-1 class: Resistance training and adequate protein intake. See GLP-1 Muscle Preservation.
What stays inside this hub
The following are not split into standalone notes:
- Formulation/device specifics (SC injection only; no oral)
- Detailed hepatic GCGR signaling subpathways (shared via GLP-1 GIP Glucagon)
- Company/licensing trivia
- Specific CYP/drug interaction data (none published)
Related notes
Mechanism:
- GLP-1 GIP Glucagon — dual GLP-1/GCGR mechanism framework
Peptide hubs:
- Retatrutide — GLP-1/GIP/glucagon triple agonist
Safety and body composition:
Comparative:
retatrutide-vs-semaglutide-vs-tirzepatide.md— GLP-1 agonist class comparison
Biometrics:
GLP-1 Body Composition.md— body composition detection model (wearable logic for GLP-1 class)
Evidence confidence summary
| Claim | Confidence | Source |
|---|---|---|
| Phase 2 obesity weight loss (~15%) | HIGH | PMID 38330987 |
| Phase 2 MASH resolution (62%) | HIGH | PMID 38847460 |
| Phase 2 T2D (HbA1c −1.71%, weight −8.7%) | HIGH | PMID 38095657 |
| GI adverse event profile | HIGH | Multiple RCTs |
| Phase 3 efficacy | LOW | Pending SYNCHRONIZE |
| Lean mass preservation | UNKNOWN | No DXA data |
| CV safety / superiority | UNKNOWN | CVOT pending |
| Superiority vs tirzepatide or retatrutide | UNKNOWN | No head-to-head |